mc-1-50
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2023 (NCT06180174)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06892145 | Phase 1 | Apr 2, 2025 | Chongqing Precision Biotech Co., Ltd, Zhejiang University |
| NCT06641024 | Phase 1 | Nov 1, 2024 | Chongqing Precision Biotech Co., Ltd, Jiao Tong University |
| NCT06180174 | Phase 1 | Dec 31, 2023 | Chongqing Precision Biotech Co., Ltd, Peking University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chongqing Precision Biotech Co., Ltd | For profit | 3 | 3 | 1 | 2023 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1